Drugs / CIN-102
CIN-102
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06899217 | Jan 2025 → May 2026 | idiopathic gastroparesis | CinDome Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05832151 | Mar 2023 → Nov 2025 | gastroparesis | CinDome Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04208698 | Feb → Mar 2020 | gastroparesis | CinDome Pharma, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04026997 | Sep 2019 → Dec 2020 | gastroparesis | CinDome Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIN-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05832151 ↗ |
| Known as | deudomperidone | “The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity...” NCT06899217 ↗2“Deuterated domperidone (deudomperidone)” NCT04208698 ↗ “study drug CIN-102 (deudomperidone)” NCT05832151 ↗ |
| Known as | Deuterated domperidone | “Deuterated domperidone (deudomperidone)” NCT04208698 ↗ |
| Route | Oral | “oral CIN-102” NCT04026997 ↗ |